Drug Type Monoclonal antibody |
Synonyms TQB2210 |
Target |
Action modulators |
Mechanism FGFR2b modulators(fibroblast growth factor receptor 2 IIIb modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Solid tumor | Phase 1 | China | 16 May 2025 | |
Advanced cancer | Phase 1 | China | 30 Apr 2025 |